Skip to main content

Open Access 08.03.2024 | original article

Hybrid PET/MRI of large vessel vasculitis

Radiation dose compared to PET/CT with view on cumulative effective dose

verfasst von: Johanna-Felicia Brauner, Sazan Rasul, Dominik Berzaczy, Daniela Beitzke, Tim Wollenweber, PD Dr. Dietrich Beitzke

Erschienen in: Wiener klinische Wochenschrift

Summary

Background

The diagnosis of large vessel vasculitis (LVV) is often challenging due to the various clinical appearances and the low prevalence. Hybrid imaging by positron emission tomography and computed tomography (PET/CT) is a highly relevant imaging modality for diagnostics and disease surveillance but may be associated with a significant amount of radiation dose especially in patients with complications.

Objective

The aim of this retrospective analysis was to compare the image quality and impact of hybrid imaging methods PET/CT and PET/MRI on the potential for dose reduction.

Methods

This retrospective single-center study included a cohort of 32 patients who were referred to PET/MRI for the evaluation of LVV, including graft infections and fever of unknown origin. This cohort was compared to a similar cohort of 37 patients who were examined with PET/CT in the same period. Mean radiation dose as well as image quality to establish a diagnosis were compared between the groups.

Results

The mean radiation dose applied in PET/MRI was significantly lower when compared to PET/CT (mean 6.6 mSV vs. 31.7 mSV; p < 0.001). This effect was based on the partially multiphasic CT protocols. At the same time, diagnostic image quality using a 4-point scale showed similar results for both imaging modalities in the work-up of LVV.

Conclusion

With PET/MRI, the radiation exposure can be significantly reduced with similar image quality and diagnostic impact. Patients with LVV have a higher risk of receiving a clinically relevant cumulative effective dose (CED) and PET/MRI should be made available to them.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

In large vessel vasculitis (LVV) symptoms are diverse and sometimes nonspecific. Both clinical and laboratory parameters may be variable and nonspecific, often leading to a delay in an exact diagnosis [1]. Complications of LVV include rupture, thrombus formation and ischemic events [2]. Infectious aortitis may cause sepsis and death if not adequately therapeutically addressed [3].
Early diagnosis and treatment initiation are therefore of tremendous importance to avoid complications. In addition, LVV often requires follow-up under treatment to monitor treatment success [4]. Clinical work-up for the evaluation of suspected LVV includes the need for appropriate imaging techniques to locate and quantify the degree of vascular inflammation. Ideally, the chosen technique should be suitable for treatment monitoring too.
Currently, hybrid computed tomography and positron emission tomography (PET/CT) is the preferred modality due to its high sensitivity (79–93%) and specificity (64–91%) for the detection as well as the follow-up examinations for LVV [5]. With this modality, inflammatory activity (with PET) and screening for vascular complications (with CT or integrated CT angiography) can be diagnosed [6, 7].
As LVV occurs more frequently in the young female population, it is important to lower radiation dose with every single examination to keep the cumulative radiation dose as low as possible while maintaining diagnostic confidence [2, 8]. According to the current German guidelines on the management of LVV, [18F]FDG PET/CT represents the gold standard for diagnosing LVV [9].
The commonly used tracer for the PET component is fluorodeoxyglucose 18F ([18F]FDG), due to the affinity of glucose for participation in metabolically active processes, as seen in inflammatory tissues in LVV [2, 10] and [18F]FDG PET/CT has proved its usefulness and robustness; however, the main drawback of the method is the radiation exposure, with values of 21.64 ± 5.20 mSv reported in the literature [11].
Combined PET/MRI might become an attractive alternative to PET/CT with a great potential to reduce the radiation exposure associated with hybrid imaging At present [18F]FDG PET/MRI is mostly used for diagnostic imaging and follow-up of oncological diseases; however, the areas of application have already been extended to cardiovascular imaging [12]. The integrated MR component offers the possibility to provide detailed anatomical and morphological information about inflammatory diseases of the aorta, without the radiation dose concerns caused by the CT component. The advantages of MRI are the excellent soft tissue characterization of the vessel wall, without exposing the patient to radiation. The aim of this study was to compare the image quality and impact of hybrid PET-MRI and PET-CT with respect to the potential for dose reduction.

Material and methods

Patients

This retrospecitve single-center analysis included 68 patients who underwent clinically indicated [18F]FDG PET/MRI or [18F]FDG PET/CT for the evaluation of suspected or already known LVV between April 2014 and June 2018. For data collection, referrals to total 36 [18F]FDG PET/MR and total 38 [18F]FDG PET/CT examinations were screened for inflammation of the large vessels, including LVV (n = 61), fever of unknown origin (FUO) (n = 4) and suspected graft infections (n = 9).
Overall 74 examinations were analyzed in the study with 51 baseline examinations (23 [18F]FDG PET/MRI and 28 [18F]FDG PET/CT) and 23 follow-up examinations under treatment or for disease control (13 [18F]FDG PET/MRI and 10 [18F]FDGPET/CT). Details are shown in Fig. 1.
Repetitive studies were observed in this analysis. In this study two patients underwent two [18F]FDG PET/MRI, one patient three [18F]FDG PET/MRI and one patient one [18F]FDG PET/MRI as well as two [18F]FDG PET/CT examinations. Follow-up examinations included stent graft infections (n = 2), inflammatory aortic aneurysms (n = 3), Takayasu arteritis (n = 7), Ormond’s disease (n = 5), giant cell arteritis (n = 3) and nonspecified vasculitis (n = 3).
If the application of contrast medium in CT or MR was contraindicated or there was reduced renal function (eGFR ≤ 30 ml/min), images without contrast were acquired in both methods. The analysis was approved by the local ethics committee (EK 1795/2018).

Patient preparation

All patients had to fast at least 5h, while drinking still water. Blood sugar levels were checked to rule out hyperglycemia prior to imaging. An intravenous administration of 245 ± 25.6 MBq [18F]FDG for PET/MRI and 280 ± 30.3 MBq [18F]FDG for PET/CT followed.

PET/MRI protocol

The [18F]FDG PET/MRI was performed using a hybrid PET/MR system (Biograph mMR, Siemens-Healthineers, Erlangen, Germany) with a PET integrated into a 3T MR system. Of the participants of the PET/MRI cohort 30 (93.75%) received 0.15 ml/kg body weight gadobutrol (Gadovist®, Bayer Schering, Austria) injected as a contrast medium. The images were acquired in 4–5 bed positions with a 5-min acquisition time per bed position. The imaging protocol consisted of a contrast-enhanced magnetic resonance angiography of the thoracoabdominal aorta with a bolus tracking technique during the administration of gadobutrol, with subtraction technology and T2 whole-body STIR and T1 for attenuation correction sequences before and after the administration of contrast medium. Of the patients two underwent PET/MRI without contrast due to renal failure.

PET/CT protocol

The [18F]FDG PET/CT was performed on a 64-row hybrid PET/CT (Biograph TruePoint 64; Siemens Healthineers) and 32 participants (88.89%) of the PET/CT cohort received a contrast agent injection (1.5 ml/kg body weight iomepro; Iomeron® 300, Bracco Austria). Due to a known allergy to the contrast media or poor renal function, four persons of the PET/CT cohort underwent a PET/CT without contrast. There were 39.47% of CT scans performed in the arterial and venous phases (either CT angiography of the thoracic aorta or the abdominal aorta). Only a venous phase was acquired in 50%, and 10.53% of the examination were performed as a low-dose scan without contrast.

Estimation of radiation dose

To compare the radiation dose of PET/CT and [18F]FDG PET/MRI, the applied values of the activity of [18F]FDG PET in MBq and the radiation dose of CT in DLP were converted into effected dose and reported in mSv. In the PET component, the weighting factor 0.027 mSv/MBq, which corresponded to the conversion value IRCP publication, was used to convert the tracer activity from MBq to mSV [13]. The weighting factor 0.015 mSv/(mGy*cm) was used according to the American Association of Physisits in Medicine Report°N096 [14] to convert the dose-length product in mGy*cm to the effective radiation dose in mSv.

Diagnostic image quality

The classification of diagnostic image quality was graded in categories from 0 to 3. For both modalities, particular emphasis was placed in the evaluation on the assessability of the soft tissue and an artifact-free and accurate superimposition of the hybrid images. The evaluation was independently performed by 2 radiologists with more than 10 years of experience in vascular imaging.
Images in category 0 were rated as nondiagnostic, because the insufficient image quality could not be used for a reliable diagnosis of LVV. Category 1 images were rated as diagnostic, although the image quality was still reduced. Images in category 2, however, were of good quality and category 3 images were of excellent quality.

Statistical analysis

Statistical analyses were performed using Microsoft Excel. Continuous results are given as mean ± standard deviation and range.
To compare effective radiation dose from [18F]FDG PET/MRI and [18F]FDG PET/CT, a t-test for unpaired samples with unequal variances was performed with a significance level at p < 0.001. The null hypothesis of a uniform variance of the parameter effective radiation dose was previously rejected by performing Levene’s test.
For the evaluation of diagnostic image quality, the interrater agreement was checked using Cohen’s kappa. For the ordinal variable image quality/diagnostic confidence a Mann-Whitney U‑test was performed for which a significance level of α ≤ 0.01 was determined.

Results

Patients

The parameters observed among the patients were age, body mass index (BMI), and blood glucose level before injection of the tracer [18F]FDG (Table 1). There was no significant difference between the patient groups regarding these parameters.
Table 1
Study population and imaging diagnoses
Characteristics of the study population
Variables
PET/MRI
PET/CT
Gender (number)
Female (11)
Female (20)
Male (21)
Male (17)
Age (years)
55 ± 17 [25–87]
58 ± 14 [24–78]
BMI (kg/m2)
26 ± 4.2 [19–36]
26 ± 5.6 [17–46]
Blood glucose level before injection of tracer (mg/dl)
107 ± 17 [65–145]
114 ± 18 [76–163]
Diagnoses
PET/MRI (N)
PET/CT (N)
No active aortitis total
21
29
Active aortitis total
15
9
Remission after active aortitis
6
5
Active aortitis, not classified
5
6
Inflammatory aortic aneurysm
5
0
Takayasu’s arteritis
4
3
Graft infection
4
0
Retroperitoneal fibrosis
3
2
Of the 74 total examinations, 24 revealed active aortitis, (15 on [18F]FDG PET/MRI and 9 on [18F]FDG PET/CT). In the remaining 50 examinations, active vascular inflammation could be ruled out (21 using [18F]FDG PET/MRI and 29 using [18F]FDG PET/CT). It should be noted that in the follow-up examinations a total of 11 remissions of previously diagnosed LVV under treatment was recorded (6 on [18F]FDG PET/MRI and 5 on [18F]FDG PET/CT). Details are shown in Table 1.

Effective dose

The effective radiation dose of the PET/MRI cohort per examination was significantly lower (p ≤ 0.05) than the PET/CT cohort per examination as shown in Table 2.
Table 2
Effective radiation dose, with results listed by imaging components
Effective radiation dose
 
mSv
MBq
mGy*cm
PET/MR
6.56 ± 0.68 [5.31–7.88]
247.06 ± 25.09 [196.5–292]
PET/CT
31.69 ± 9.12 [12.89–54.33]
PET component
7.57 ± 0.83 [6.37–9.72]
280.37 ± 30.74 [235.93–360]
CT component
25.26 ± 8.87 [14.46–50.42]
1684 ± 591.33 [964–3361]
A t-test for unpaired samples with unequal variances with a significance level at p < 0.001 showed that there was no significant difference between the radiation dose of PET (MBq) components viewed alone.
Of the patients of the PET/CT cohort three received a radiation dose higher than 50 mSv for one examination. Regarding the cumulative dose for each patient there was no patient of the PET/MRI cohort who received repetitive [18F]FDG PET/MRI who was exposed to 50 mSv or more. One patient who underwent two [18F]FDG PET/CT and one [18F]FDG PET/MRI examinations during the period of this analysis was exposed to a cumulative radiation dose of 92.23 mSv. None of the patients had a cumulative dose of 100 mSv or above. The results of the main parameter effective dose are shown in Table 2 and Fig. 2.

Image quality

The image quality of [18F]FDG PET/MRI was rated in all cases as good (category 2) or excellent image quality (category 3). In [18F]FDG PET/CT, only a single scan was rated as diagnostic but image quality reduced (category 1) (see Table 3). This rating was based on multiple motion and breathing artefacts during CT acquisition. The analysis of diagnostic confidence in image quality showed no significant difference between the two groups. There were moderate interobserver agreements for [18F]FDG PET/MRI (κ = 0.366) and [18F]FDG PET/CT (κ = 0.578) for image quality. Figures 3 and 4 demonstrate representative [18F]FDG PET/CT and [18F]FDG PET/MR images from this study.
Table 3
Results of image quality
Image quality
Category
PET/MRI
PET/CT
Reader 1
Reader 2
Reader 1
Reader 2
0–3
Number
Percent
Number
Percent
Number
Percent
Number
Percent
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
1
2.63
2
5
13.89
4
11.11
2
5.26
2
5.26
3
31
86.11
32
88.89
36
94.74
35
92.11

Discussion

The main finding in this study was that [18F]FDG PET/MRI and [18F]FDG PET/CT are equally well suited as a diagnostic tool in the imaging work-up of LVV while [18F]FDG PET/MRI achieved significantly lower radiation doses.
Especially in diseases that require repetitive imaging, avoiding unnecessary radiation doses has become more important in medical imaging with the aim to reduce the cumulative effective dose. [15, 16].
For the work-up of LVV and FUO in our institution, the effective radiation dose per examination was 6.56 mSv, on average in the PET/MRI group, while it was 31.69 mSv, on average in the PET/CT group. This difference is mainly based on the lack of radiation exposure of the often multiphasic CT component; however, it should be noted that there are differences between the two modalities regarding the quantitative PET component. The MR images are not correlated with tissue attenuation coefficients as CT images are. The reliable determination of the tracer uptake in a PET/MRI requires an attenuation correction of the PET data, which calculates an attenuation based on soft tissue, bone, and hardware components.
Our analysis showed that about 78% of the radiation dose could be reduced while providing the same diagnostic quality in the evaluation of LVV. This is especially of importance when multiple examinations might become necessary in the follow-up of inflammatory LVV [17, 18]. A lower applied radiation dose in every single examination to minimize stochastic radiation effects from cumulative radiation dose might reduce the carcinogenic risk of imaging in this cohort of patients. In this retrospective study, 14 [18F]FDG PET/MRI and 8 [18F]FDG PET/CT examinations were performed on patients younger than 51 years of age. The increase in the risk of developing fatal cancer in this cohort is estimated at 5% per administered Sv for the general population. While this risk increases to 15% per Sv in children, it decreases to 1% per Sv in people in their seventh decade of life [19]. Especially for young patients, PET/MRI might be preferable because it is a lower-dose variant with at least the same diagnostic confidence as PET/CT.
Due to the often unclear clinical presentation, it is assumed that other radiological diagnostics have already taken place before the specific examination using PET/MRI or PET/CT. Because the CT is a readily available imaging technique that is firmly established in the diagnosis of a variety of diseases, there has been a dramatic increase in average patient radiation exposure since its invention. Therefore, it is even more important to be able to save radiation doses in the future [15, 20, 21].
The PET/MRI combines the strength of these two single modalities. The hybrid imaging method enables the acquisition of information about the severity of the inflammation (with PET) and about the anatomical changes via MRI [22]. It is a relatively novel imaging technique whose areas of application are currently expanding [23]. In imaging of LVV, not only is the extent of the inflammation of importance but also anatomical changes are decisive for diagnosis and treatment surveillance. Thus, not every imaging method is suitable to reflect both aspects of this disease. Previous studies have already suggested that hybrid imaging methods [18F]FDG PET/CT and [18F]FDG PET/MRI provide the most reliable information on both aspects. The [18F]FDG PET/CT has already been well studied in this application [24, 25]. A study by Clemente et al. examined childhood-onset Takayasu’s arteritis patients using [18F]FDG PET/MRI and compared cohorts with positive PET and positive MRA with positive PET but negative MRA. It was shown that the hybrid method added information about the extent of the inflammation with the PET component, which is not presented in every patient in an MRA examination alone [26].
Cerne et al. showed that PET/MRI delivers more information about inflammatory markers in the diagnosis and follow-up of LVV compared to laboratory findings because this imaging method characterizes the severity and the extent of the inflammation. Inflammatory markers proved to be too unspecific and, compared to PET/MRI do not allow a statement about anatomical changes and the extent of the inflammation [27].
Laurent et al. evaluated a correlation between the clinical and laboratory presentation of patients with Takayasu arteritis and giant cell arteritis, and the results of imaging using [18F]FDG PET/MRI. The image analysis was graded based on the tracer uptake in the vessels, which was compared to the tracer uptake in the liver, using grading from 0 to 3, and by measuring the thickening and enhancement of the aortic wall on delayed enhancement MR images. This study showed that the tracer uptake in the vessels correlated with the quantity of the inflammation, proven by the clinical and laboratory results. In conclusion, [18F]FDG PET/MRI might even be suitable to replace invasive methods such as biopsies of the temporal artery, or as a diagnostic tool for giant cell arteritis [28], and appears to be a suitable method for detection and follow-up examinations in LVV; however, that study did not contain any comparison to other imaging methods.
In another study, Einspieler et al. drew comparisons regarding visual and quantitative parameters between both hybrid-imaging methods, [18F]FDG PET/MRI and [18F]FDG PET/CT, in patients with known LVV. The image scoring revealed the intensity of the arterial uptake of the tracer in contrast to the uptake into the liver. The statistical analysis was made with the measurements SUVmax and the target to background ratio for each measured vascular segment. The calculation of the target background ratio SUVmax was divided by SUVmin using a region of interest in the blood pool. This study proved that both modalities are equivalent with respect to the visual scores compared to the measured inflammatory parameters [29].
In contrast to the studies listed above, initial diagnoses of LVV were included in this study. The data presented in our paper is in line with these publications showing that imaging-based diagnosis using [18F]FDG PET/MR appears to be possible at a low radiation dose in patients suspected of having LVV; however, previous studies did not compare [18F]FDG PET/CT vs. [18F]FDG PET/MR in terms of effective radiation dose of these two modalities. The present study was the first to show that [18F]FDG PET/MRI offers equivalent diagnostic image quality in the work-up of suspected inflammatory vascular disease when compared to [18F]FDG PET/CT with a relatively high sample size.
Current studies are researching new tracers that are intended to further improve the diagnosis and follow-up of LVV. As glucose acts in metabolically active processes, which occur physiologically to an increased extent in the brain and myocardium, the diagnosis of, for example, temporal arteritis or the assessment of the coronary arteries in LVV can be misleading. In addition, with the use of [18F]FDG it is not possible to distinguish between processes of active inflammation, chronic vascular remodeling, and residual disease activity after treatment. According to a study by Ćorović et al., the tracer [68Ga]-dotatate, which binds somatostatin receptor 2 (SSTR2), already used in neuroendocrine tumor diagnostics, seems promising. The SSTR2 is expressed by macrophages during inflammation and localizes around CD68+ macrophages, such as those found in inflamed carotid atherosclerotic plaques [30]. In addition, other promising tracers are currently being investigated with a view to expanding their areas of application. Some examples include [68Ga]-pentixafor, a PET tracer that was originally developed for cancer imaging by binding to CXCR4, which is expressed on several proinflammatory immune cell types, or 68Ga-FAPI, which binds to the transmembrane serine protease fibroblast activation protein‑α (FAP), whose expression is high in activated stromal fibroblasts at sites of tissue remodeling and is found primarily in pathological conditions such as fibrosis, scar/granulation tissue, cancer, and arthritis [31].
However, current limitations of PET/MRI include its limited availability worldwide and its often predominant use in the work-up and staging of oncologic disease. Furthermore, access to this modality is sometimes hindered by contraindications for MRI such as claustrophobia and non-MR-compatible implants or non-MR pacemaker systems; however, currently, even pacemakers are often deemed MR-compatible, which might improve access to PET/MRI in the future [32]. There are relative contraindications for contrast medium such as terminal kidney failure.
With respect to the investment costs and the ongoing operational expenses, PET/MRI is far more expensive than PET/CT. The costs are related not only to the price of a PET/MR hybrid device itself, but to the availability of the radiological staff that can operate this new device. There is the longer duration required for an MRI compared to a CT scan. For cancer patients, the costs of the routine staging or follow-up per examination is about 50% higher for PET/MRI than for PET/CT [33].
Although the cumulative radiation dose is a strong argument for establishing PET/MRI in the diagnosis of LVV, there are applications where PET/CT is more effective. PET/CT with CT angiography is advantageous for planning interventions in cases of complications like stenosis or aneurysm formation as a result of inflammation.
In terms of the radiation exposure derived from PET/CT, it should be noted that currently, a new generation of modern PET/CT scanners are entering the market. These scanners can provide whole-body scans with ultra-low dose (e.g., 0.37MBq/kg) protocols that show no significant difference in quantitative and qualitative image analysis [34]. These long axial field of view (LAFOV) PET/CT scanners show an increased signal-to-noise ratio and can achieve higher sensitivity based on a higher count density than the scanner used in our analysis. In addition, modern postprocessing methods, such as ultrahigh sensitivity (UHS) reconstruction modes on these new scanners, may cut the PET acquisition time in half, which would reduce the examination time [35]; however, to generate whole-body parametric PET images, a minimum of 45–60 min of scanning is required due to the slow kinetics of 18F-FDG.

Limitations

The main limitation of this study is the small patient population and its retrospective nature in a single center. Different CT protocols were included in the PET/CT cohort, resulting in an elevated CT radiation dose when compared to CT scans without contrast alone. It should be noted that the PET/CT scanner used in this study is already outdated when compared with recent scanner technology. Additionally, a non-significantly higher 18F-FDG dose had to be applied in PET/CT when compared to PET/MRI as the PET component of the currently available PET/MRI system has a higher sensitivity.
In the risk-benefit balance, the radiation dose savings outweigh the limitations of PET/MRI. The disadvantages of PET/MRI, as with MRI, are its contraindications for use in individuals with claustrophobia, metallic implants, and non-MR-compatible pacemakers, Furthermore, the low availability due to the high costs currently limits the further spread of PET/MR [33].
Although comparable cohorts were considered in this study, both examinations were not performed on a single patient, which precludes exact comparability.

Conclusion

In conclusion, [18F]FDG PET MRI might be an attractive alternative for the diagnostic work-up of LVV, with the advantage of a significantly lower radiation dose when compared to [18F]FDG PET/CT. The advantages of PET/MRI over PET/CT are based on significantly lower radiation exposure due to the lack of the radiation burden of the CT component. As diagnostic image quality is maintained, PET/MRI appears to be especially attractive for patients who require imaging follow-up.

Conflict of interest

J.-F. Brauner, S. Rasul, D. Berzaczy, D. Beitzke, T. Wollenweber and D. Beitzke declare that they have no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Cimmino MA, Camellino D. Large vessel vasculitis: Is it more common than usually assumed? Reumatismo. Page. Publications: Press; 2017. pp. 143–6. Cimmino MA, Camellino D. Large vessel vasculitis: Is it more common than usually assumed? Reumatismo. Page. Publications: Press; 2017. pp. 143–6.
2.
Zurück zum Zitat Gornik HL, Creager MA. Aortitis. Circulation. 2008;p:3039–51.CrossRef Gornik HL, Creager MA. Aortitis. Circulation. 2008;p:3039–51.CrossRef
3.
Zurück zum Zitat Deipolyi AR, Czaplicki CD, Oklu R. Inflammatory and infectious aortic diseases. Cardiovasc Diagn Ther Ame Publ Company;. 2018;p:S61–70.CrossRef Deipolyi AR, Czaplicki CD, Oklu R. Inflammatory and infectious aortic diseases. Cardiovasc Diagn Ther Ame Publ Company;. 2018;p:S61–70.CrossRef
4.
Zurück zum Zitat Barra L, Kanji T, Malette J, Pagnoux C. Imaging modalities for the diagnosis and disease activity assessment of Takayasu’s arteritis: A systematic review and meta-analysis. Autoimmun. Rev. Elsevier B.V.; 2018. p. 175–87. Barra L, Kanji T, Malette J, Pagnoux C. Imaging modalities for the diagnosis and disease activity assessment of Takayasu’s arteritis: A systematic review and meta-analysis. Autoimmun. Rev. Elsevier B.V.; 2018. p. 175–87.
5.
Zurück zum Zitat Treglia G. Diagnostic Performance of 18F-FDG PET/CT in Infectious and Inflammatory Diseases according to Published Meta-Analyses. Contrast Media Mol Imaging. Hindawi Ltd. and John Wiley and Sons, Inc.; 2019;2019. Treglia G. Diagnostic Performance of 18F-FDG PET/CT in Infectious and Inflammatory Diseases according to Published Meta-Analyses. Contrast Media Mol Imaging. Hindawi Ltd. and John Wiley and Sons, Inc.; 2019;2019.
6.
Zurück zum Zitat Olthof SC, Krumm P, Henes J, Nikolaou K, la Fougère C, Pfannenberg C, et al. Imaging giant cell arteritis and Aortitis in contrast enhanced 18F-FDG PET/CT: Which imaging score correlates best with laboratory inflammation markers? Eur J Radiol. Elsevier Ireland Ltd; 2018;99:94–102. Olthof SC, Krumm P, Henes J, Nikolaou K, la Fougère C, Pfannenberg C, et al. Imaging giant cell arteritis and Aortitis in contrast enhanced 18F-FDG PET/CT: Which imaging score correlates best with laboratory inflammation markers? Eur J Radiol. Elsevier Ireland Ltd; 2018;99:94–102.
7.
Zurück zum Zitat Kobayashi Y, Ishii K, Oda K, Nariai T, Tanaka Y, Ishiwata K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. J Nucl Med Soc Nucl Med. 2005;46:917–22. Kobayashi Y, Ishii K, Oda K, Nariai T, Tanaka Y, Ishiwata K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. J Nucl Med Soc Nucl Med. 2005;46:917–22.
8.
Zurück zum Zitat Russo RAG, Katsicas MM. Takayasu arteritis. Front Pediatr Front Media Sa;. 2018;. Russo RAG, Katsicas MM. Takayasu arteritis. Front Pediatr Front Media Sa;. 2018;.
9.
Zurück zum Zitat Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, et al. S2k-Leitlinie: Management der Großgefäßvaskulitiden. Z Rheumatol. Springer Medizin; 2020;79:67–95. Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, et al. S2k-Leitlinie: Management der Großgefäßvaskulitiden. Z Rheumatol. Springer Medizin; 2020;79:67–95.
10.
Zurück zum Zitat Ninan J, Lester S, Hill C. Giant cell arteritis. Best Pract. Res Clin Rheumatol Bailliere Tindall Ltd;. 2016;p:169–88.CrossRef Ninan J, Lester S, Hill C. Giant cell arteritis. Best Pract. Res Clin Rheumatol Bailliere Tindall Ltd;. 2016;p:169–88.CrossRef
11.
Zurück zum Zitat Li Y, Jiang L, Wang H, Cai H, Xiang Y, Li L. Effective radiation dose of 18F-FDG PET/CT: How much does diagnostic CT contribute? Radiat Prot Dosimetry. Oxf Univ Press. 2019;187:183. Li Y, Jiang L, Wang H, Cai H, Xiang Y, Li L. Effective radiation dose of 18F-FDG PET/CT: How much does diagnostic CT contribute? Radiat Prot Dosimetry. Oxf Univ Press. 2019;187:183.
12.
Zurück zum Zitat Robson PM, Dey D, Newby DE, Berman D, Li D, Fayad ZA, et al. MR/PET Imaging of the Cardiovascular System. JACC Cardiovasc. Imaging. Elsevier Inc.; 2017. p. 1165–79. Robson PM, Dey D, Newby DE, Berman D, Li D, Fayad ZA, et al. MR/PET Imaging of the Cardiovascular System. JACC Cardiovasc. Imaging. Elsevier Inc.; 2017. p. 1165–79.
13.
Zurück zum Zitat ICRP. Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publ. Publi, Vol. 76. ICRP. 1988. ICRP. Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publ. Publi, Vol. 76. ICRP. 1988.
14.
Zurück zum Zitat McCollough C, Cody D, Edyvean S, Geise R, Gould B, Keat N, et al. The Measurement, Reporting, and Management of Radiation Dose in. CT. 2008;. McCollough C, Cody D, Edyvean S, Geise R, Gould B, Keat N, et al. The Measurement, Reporting, and Management of Radiation Dose in. CT. 2008;.
15.
Zurück zum Zitat Brenner DJ, Hricak H. Radiation exposure from medical imaging: Time to regulate? JAMA—J. Am. Med. Assoc. JAMA; 2010. p. 208–9. Brenner DJ, Hricak H. Radiation exposure from medical imaging: Time to regulate? JAMA—J. Am. Med. Assoc. JAMA; 2010. p. 208–9.
16.
Zurück zum Zitat Thomas GA, Symonds P. Radiation Exposure and Health Effects—is it Time to Reassess the Real Consequences? Clin. Oncol. Elsevier; 2016. pp. 231–6. Thomas GA, Symonds P. Radiation Exposure and Health Effects—is it Time to Reassess the Real Consequences? Clin. Oncol. Elsevier; 2016. pp. 231–6.
17.
Zurück zum Zitat Giraudo C, Raderer M, Karanikas G, Weber M, Kiesewetter B, Dolak W, et al. 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance in lymphoma: Comparison with 18F-fluorodeoxyglucose positron emission tomography/computed tomography and with the addition of magnetic resonance diffusion-weighted imaging. Invest Radiol. Lippincott Williams and Wilkins; 2016;51:163–9. Giraudo C, Raderer M, Karanikas G, Weber M, Kiesewetter B, Dolak W, et al. 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance in lymphoma: Comparison with 18F-fluorodeoxyglucose positron emission tomography/computed tomography and with the addition of magnetic resonance diffusion-weighted imaging. Invest Radiol. Lippincott Williams and Wilkins; 2016;51:163–9.
18.
Zurück zum Zitat Lücke C, Oppolzer B, Werner P, Foldyna B, Lurz P, Jochimsen T, et al. Comparison of volumetric and functional parameters in simultaneous cardiac PET/MR: feasibility of volumetric assessment with residual activity from prior PET/CT. Eur Radiol. Springer Verlag; 2017;27:5146–57. Lücke C, Oppolzer B, Werner P, Foldyna B, Lurz P, Jochimsen T, et al. Comparison of volumetric and functional parameters in simultaneous cardiac PET/MR: feasibility of volumetric assessment with residual activity from prior PET/CT. Eur Radiol. Springer Verlag; 2017;27:5146–57.
19.
Zurück zum Zitat Hall EJ. Radiation biology for pediatric radiologists. Pediatr Radiol. Pediatr Radiol. 2009. Hall EJ. Radiation biology for pediatric radiologists. Pediatr Radiol. Pediatr Radiol. 2009.
20.
Zurück zum Zitat Brenner DJ, Hall EJ Computed Tomography N Engl J Med Massachusetts Medical Society. 357. 2007. pp. 2277–84. Brenner DJ, Hall EJ Computed Tomography N Engl J Med Massachusetts Medical Society. 357. 2007. pp. 2277–84.
21.
Zurück zum Zitat Mettler FA, Bhargavan M, Faulkner K, Gilley DB, Gray JE, Ibbott GS, et al. Radiologic and nuclear medicine studies in the United States and worldwide: Frequency, radiation dose, and comparison with other radiation sources—1950–2007. Radiology. Radiology. 2009;253:520–31.CrossRefPubMed Mettler FA, Bhargavan M, Faulkner K, Gilley DB, Gray JE, Ibbott GS, et al. Radiologic and nuclear medicine studies in the United States and worldwide: Frequency, radiation dose, and comparison with other radiation sources—1950–2007. Radiology. Radiology. 2009;253:520–31.CrossRefPubMed
22.
Zurück zum Zitat Quinn KA, Ahlman MA, Malayeri AA, Marko J, Civelek AC, Rosenblum JS, et al. Comparison of magnetic resonance angiography and 18 F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. BMJ Publishing. Group. 2018;77:1166–72. Quinn KA, Ahlman MA, Malayeri AA, Marko J, Civelek AC, Rosenblum JS, et al. Comparison of magnetic resonance angiography and 18 F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. BMJ Publishing. Group. 2018;77:1166–72.
23.
Zurück zum Zitat Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes AP, Larson PEZ, et al. PET/MRI: Where might it replace PET/CT? J. Magn. Reson. Imaging. John Wiley and Sons Inc.; 2017. p. 1247–62. Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes AP, Larson PEZ, et al. PET/MRI: Where might it replace PET/CT? J. Magn. Reson. Imaging. John Wiley and Sons Inc.; 2017. p. 1247–62.
24.
Zurück zum Zitat Selvaraj A, Francis N, Harky A, Goli G, Bashir M. Imaging modalities in the management of aortitis. Indian J. Thorac. Cardiovasc. Surg. Springer; 2019. p. 67–71. Selvaraj A, Francis N, Harky A, Goli G, Bashir M. Imaging modalities in the management of aortitis. Indian J. Thorac. Cardiovasc. Surg. Springer; 2019. p. 67–71.
25.
Zurück zum Zitat Schäfer VS, Jin L, Schmidt WA. Imaging for Diagnosis, Monitoring, and Outcome Prediction of Large Vessel. Vasc Curr Rheumatol Rep Springer;. 2020;. Schäfer VS, Jin L, Schmidt WA. Imaging for Diagnosis, Monitoring, and Outcome Prediction of Large Vessel. Vasc Curr Rheumatol Rep Springer;. 2020;.
26.
Zurück zum Zitat Clemente G, de Souza AW, Leão Filho H, Coelho FMA, Buchpiguel C, Lima M, et al. Does [18F]F-FDG-PET/MRI add metabolic information to magnetic resonance image in childhood-onset Takayasu’s arteritis patients? A multicenter case series. Adv Rheumatol. BioMed Central Ltd; 2022;62. Clemente G, de Souza AW, Leão Filho H, Coelho FMA, Buchpiguel C, Lima M, et al. Does [18F]F-FDG-PET/MRI add metabolic information to magnetic resonance image in childhood-onset Takayasu’s arteritis patients? A multicenter case series. Adv Rheumatol. BioMed Central Ltd; 2022;62.
27.
Zurück zum Zitat Cerne JW, Liu S, Umair M, Pathrose A, Moore JE, Allen BD, et al. Combined modality PET/MR for the detection of severe large vessel vasculitis. Eur J Hybrid Imaging. Springer Nature; 2022;6. Cerne JW, Liu S, Umair M, Pathrose A, Moore JE, Allen BD, et al. Combined modality PET/MR for the detection of severe large vessel vasculitis. Eur J Hybrid Imaging. Springer Nature; 2022;6.
28.
Zurück zum Zitat Laurent C, Ricard L, Fain O, Buvat I, Adedjouma A, Soussan M, et al. PET/MRI in large-vessel vasculitis: clinical value for diagnosis and assessment of disease activity. Sci Rep. Nature Publishing Group; 2019;9. Laurent C, Ricard L, Fain O, Buvat I, Adedjouma A, Soussan M, et al. PET/MRI in large-vessel vasculitis: clinical value for diagnosis and assessment of disease activity. Sci Rep. Nature Publishing Group; 2019;9.
29.
Zurück zum Zitat Einspieler I, Thürmel K, Pyka T, Eiber M, Wolfram S, Moog P, et al. Imaging large vessel vasculitis with fully integrated PET/MRI: a pilot study. Eur J Nucl Med Mol Imaging. Springer Berlin; 2015;42:1012–24. Einspieler I, Thürmel K, Pyka T, Eiber M, Wolfram S, Moog P, et al. Imaging large vessel vasculitis with fully integrated PET/MRI: a pilot study. Eur J Nucl Med Mol Imaging. Springer Berlin; 2015;42:1012–24.
30.
Zurück zum Zitat Ćorović A, Wall C, Nus M, Gopalan D, Huang Y, Imaz M, et al. Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis. J Am Coll Cardiol Elsevier Inc;. 2023;81:336–54.CrossRef Ćorović A, Wall C, Nus M, Gopalan D, Huang Y, Imaz M, et al. Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis. J Am Coll Cardiol Elsevier Inc;. 2023;81:336–54.CrossRef
31.
Zurück zum Zitat Iking J, Staniszewska M, Kessler L, Klose JM, Lückerath K, Fendler WP, et al. Imaging inflammation with positron emission tomography. Biomedicines. MDPI AG; 2021. pp. 1–24. Iking J, Staniszewska M, Kessler L, Klose JM, Lückerath K, Fendler WP, et al. Imaging inflammation with positron emission tomography. Biomedicines. MDPI AG; 2021. pp. 1–24.
32.
Zurück zum Zitat Vigen KK, Reeder SB, Hood MN, Steckner M, Leiner T, Dombroski DA, et al. Recommendations for Imaging Patients With Cardiac Implantable Electronic Devices (CIEDs). J Magn Reson Imaging. United States; 2021;53:1311–7. Vigen KK, Reeder SB, Hood MN, Steckner M, Leiner T, Dombroski DA, et al. Recommendations for Imaging Patients With Cardiac Implantable Electronic Devices (CIEDs). J Magn Reson Imaging. United States; 2021;53:1311–7.
33.
Zurück zum Zitat Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, et al. PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging. Springer; 2020;47:51–60. Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, et al. PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging. Springer; 2020;47:51–60.
34.
Zurück zum Zitat Tan H, Qi C, Cao Y, Cai D, Mao W, Yu H, et al. Ultralow-dose [18F]FDG PET/CT imaging: demonstration of feasibility in dynamic and static images. Eur Radiol. Deutschland GmbH: Springer; 2023. Tan H, Qi C, Cao Y, Cai D, Mao W, Yu H, et al. Ultralow-dose [18F]FDG PET/CT imaging: demonstration of feasibility in dynamic and static images. Eur Radiol. Deutschland GmbH: Springer; 2023.
35.
Zurück zum Zitat Mingels C, Weidner S, Sari H, Buesser D, Zeimpekis K, Shi K, et al. Impact of the new ultra-high sensitivity mode in a long axial field-of-view PET/CT. Ann Nucl Med Springer;. 2023;37:310.CrossRef Mingels C, Weidner S, Sari H, Buesser D, Zeimpekis K, Shi K, et al. Impact of the new ultra-high sensitivity mode in a long axial field-of-view PET/CT. Ann Nucl Med Springer;. 2023;37:310.CrossRef
Metadaten
Titel
Hybrid PET/MRI of large vessel vasculitis
Radiation dose compared to PET/CT with view on cumulative effective dose
verfasst von
Johanna-Felicia Brauner
Sazan Rasul
Dominik Berzaczy
Daniela Beitzke
Tim Wollenweber
PD Dr. Dietrich Beitzke
Publikationsdatum
08.03.2024
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-024-02336-2